Chemotherapy and Radiotherapy in Pancreatic Cancer

  • Mario Scartozzi
  • Chiara Pierantoni
  • Alessandra Pagliacci
  • Stefano Cascinu
Part of the Updates in Surgery book series (UPDATESSURG)


Pancreatic cancer continues to be a highly lethal disease, with approximately 37,000 estimated new cases in the USA in 2007 in both sexes, representing the fourth leading cause of cancer death [1]. Surgery remains the only treatment with a curative potential for local disease, but only 15–20% of patients have resectable disease at the time of diagnosis [2], and the median survival of radically resected patients is approximately 20 months, with a 2-year survival rate ranging from 20 to 40%. Adjuvant chemotherapy or radiotherapy has been assessed in several trials in an attempt to improve patients’ prognosis.


Pancreatic Cancer Clin Oncol Radiat Oncol Biol Phys Well Supportive Care Metastatic Pancreatic Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jemal A, Siegel R, Ward E et al (2007) Cancer statistics 2007. CA Cancer J Clin 57:43–66CrossRefPubMedGoogle Scholar
  2. 2.
    Li D, Xie K, Wolff R, Abruzzese JL (2004) Pancreatic cancer. Lancet 363:1049–1057CrossRefPubMedGoogle Scholar
  3. 3.
    Burris III HA, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413PubMedGoogle Scholar
  4. 4.
    Kalser MH, Ellemberg SS (1985) Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120:899–903PubMedGoogle Scholar
  5. 5.
    Klinkenbjil J, Jekel J, Sahmoud T et al (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 230: 776–784CrossRefGoogle Scholar
  6. 6.
    Garofalo MC, Regine WF, Tan MT (2006) On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer. Ann Surg 244:332–333CrossRefPubMedGoogle Scholar
  7. 7.
    Picozzi VJ, Kozarak RA, Traverso LW (2003) Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 185:476–480CrossRefPubMedGoogle Scholar
  8. 8.
    Knaebel HP, Marten A, Schmitz-Winnenthal H et al (2005) Phase III trial of postoperative cisplatin, interferon alpha-2b and 5-FU alone for patients with resected pancreatic adenocarcinoma. CapRI: study protocol [ISRCTN6286675P]. BMC Cancer 5:37CrossRefPubMedGoogle Scholar
  9. 9.
    Yeo CJ, Abrams RA, Grochow LB et al (1997) Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 225:621–636CrossRefPubMedGoogle Scholar
  10. 10.
    Regine WF, Winter KW, Abrams R et al (2006) RTOG9704 a phase III study of adjuvant pre and postchemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. J Clin Oncol 24(Suppl 18s):4007Google Scholar
  11. 11.
    Bakkevold KE, Arnesjø B, Dahl O et al (1993) Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater results of a controlled, prospective, randomized multicentre study. Eur J Cancer 29A:698–703CrossRefPubMedGoogle Scholar
  12. 12.
    Takada T, Amano H, Yasuda H et al (2002). Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized trial in patients with resected pancreaticobiliary carcinoma. Cancer 95:1685–1695CrossRefPubMedGoogle Scholar
  13. 13.
    Oettle H, Post S, Neuhaus P et al (2007) Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer. JAMA 3:267–277CrossRefGoogle Scholar
  14. 14.
    Neoptolemos JP, Stocken DD, Friess H et al (2004). A randomized trial of chemotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200–1210CrossRefPubMedGoogle Scholar
  15. 15.
    Stocken DD, Büchler MW, Dervenis C et al (2005) Meta-analysis of randomized adjuvant therapy trials for pancreatic cancer. Br J Cancer 92:1372–1381CrossRefPubMedGoogle Scholar
  16. 16.
    Spitz FR, Abruzzese JL, Lee JE et al (1997) Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 15:928–937PubMedGoogle Scholar
  17. 17.
    Varadhachary GR, Evans DE, Crane C et al (2002) Initial results of preoperative gemcitabine based chemoradiation for resectable pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 21:Abs 516. Available at www.asco.orgGoogle Scholar
  18. 18.
    Evans DB, Abruzzese JL, Willett CG (2001) Cancer of the pancreas. In: Devita VT Jr, Hellman S, Rosenberg SA (eds) Cancer. Principles and practice of oncology, 6th edn. Philadelphia: Lippincott Williams and Wilkins, pp 1126–1161Google Scholar
  19. 19.
    Moertel CG, Childs DS Jr, et al (1969) Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2:865–867CrossRefPubMedGoogle Scholar
  20. 20.
    Moertel CG, Frytak S, Hahn RG et al (1981) Therapy of locally unresectable pancreatic carcinoma. A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48: 1705–1710CrossRefPubMedGoogle Scholar
  21. 21.
    Douglass HO (1988) Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone; Gastrointestinal Tumor Study Group. J Natl Cancer Inst 80:751–755CrossRefGoogle Scholar
  22. 22.
    Klassen J, John M, Maclntyre M et al (1985) Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluououracil. An Eastern Cooperative Oncology Group Study. J Clin Oncol 3:373–378Google Scholar
  23. 23.
    Chauffert B, Mornex F, Bonnetain F et al (2006) Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCDSFRO study. J Clin Oncol 24(Suppl 18):A4008Google Scholar
  24. 24.
    McGinn CJ, Zalupski MM, Shureiqi I et al (2001) Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19:4202–4208PubMedGoogle Scholar
  25. 25.
    Blackstok AW, Bernard SA, Richards F et al (1999) Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 17:2208–2212Google Scholar
  26. 26.
    Epelbaum R, Rosenblat E, Nasrallah S et al (2002) Phase II study of gemcitabine (GEM) combined with radiation therapy (RT) in localized, unresectable pancreatic cancer. J Surg Oncol 81:138–143CrossRefPubMedGoogle Scholar
  27. 27.
    Crane CH, Abbruzzese JL, Evans DB et al (2002) Is the therapeutic index better with gemcitabine based chemoradiation than with 5-fluorouracil based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 52:1293–1302CrossRefPubMedGoogle Scholar
  28. 28.
    Li CP, Chao Y, Chi KH et al (2003) Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. In J Radiat Oncol Biol Phys 57:98–104CrossRefGoogle Scholar
  29. 29.
    Shinchi H, Takao S, Noma H et al (2002) Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 53:146–150PubMedGoogle Scholar
  30. 30.
    Huguet F, Andrè T, Hamel P et al (2007) Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR Phase II and III studies. J Clin Oncol 25:326–331CrossRefPubMedGoogle Scholar
  31. 31.
    Glimelius B, Hoffman K, Sjoden PO et al (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7:593–600PubMedGoogle Scholar
  32. 32.
    Palmer KR, Cereda S, Passoni P et al (1994) Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 81:882–885CrossRefPubMedGoogle Scholar
  33. 33.
    Sultana A, Smith CT, Cunnigham D et al (2007) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25:2607–2615CrossRefPubMedGoogle Scholar
  34. 34.
    Hansen R, Quebbman E, Ritch P et al (1988) Continuous 5-fluorouracil infusion in carcinoma of the pancreas. Am J Med Sci 295:91–93CrossRefPubMedGoogle Scholar
  35. 35.
    Ducreux M, Rouguer P, Pignon JP et al (2002) A randomized trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 13:1185–1191CrossRefPubMedGoogle Scholar
  36. 36.
    Cartwright TH, Cohn A, Varkey JA et al (2001) Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 20:160–164CrossRefGoogle Scholar
  37. 37.
    Abbruzzese JL (1996) Phase I studies with the novel nucleoside analogue gemcitabine. Semin Oncol 23:25–31PubMedGoogle Scholar
  38. 38.
    Casper E, Green M, Kelsen D (1994) Phase II trial of gemcitabine (2,2-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12:29–34CrossRefPubMedGoogle Scholar
  39. 39.
    Carmichael J, Fink U, Russel RCG et al (1996) Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73:101–105PubMedGoogle Scholar
  40. 40.
    Maisey N, Chau I, Cunningham D et al (2002) Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 20:3130–3136CrossRefPubMedGoogle Scholar
  41. 41.
    Tempero M, Plunkett W, Ruiz Van Haperen V et al (2003) Randomized phase I comparison of dose-intense gemcitabine. Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402–3408CrossRefPubMedGoogle Scholar
  42. 42.
    Poplin E, Levy D, Berlin J et al (2006) Phase III trial of gemcitabine (30 min infusion) versus gemcitabine fixed-dose rate infusion (FDR) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J Clin Oncol 24(Suppl 18):LBA4004Google Scholar
  43. 43.
    Berlin JD, Catalano P, Thomas JP et al (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial E2297. J Clin Oncol 20:3270–3275CrossRefPubMedGoogle Scholar
  44. 44.
    Heinemann V, Qietzsch D, Gieseler F et al (2006) Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic carcinoma. J Clin Oncol 24:3946–3952CrossRefPubMedGoogle Scholar
  45. 45.
    Colucci G, Giuliani F, Gebbia V et al (2002). Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma. A prospective randomized phase III of the Gruppo Oncologico dell’Italia Meridionale. Cancer 94:902–910CrossRefPubMedGoogle Scholar
  46. 46.
    Louvet C, Labianca R, Hammel P et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509–3516CrossRefPubMedGoogle Scholar
  47. 47.
    Herrmann R, Bodoky G, Rushstaller T et al (2007) Gemcitabine (G) plus capecitabine versus G alone in locally advanced or metastatic pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). J Clin Oncol 25:2212–2217CrossRefPubMedGoogle Scholar
  48. 48.
    Rocha Lima CM, Green MR, Rotche R et al (2004) Irinotecan plus gemcitabine results in no advange compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22:3776–3783CrossRefPubMedGoogle Scholar
  49. 49.
    Abou-Alfa GK, Letourneau R, Harker G et al (2006) Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 24:4441–4447CrossRefPubMedGoogle Scholar
  50. 50.
    Stathopoulos GB, Syrigos K, Aravantinos G et al (2006) A multicenter phase II trial comparing irinotecan—gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 95:587–592CrossRefPubMedGoogle Scholar
  51. 51.
    Richards D, Oettle H, Ramanathan RK et al (2005) A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16:1639–1645CrossRefPubMedGoogle Scholar
  52. 52.
    Reni M, Cordio S, Milandri C et al (2005) Gemcitabine versus cisplatin, epirubicin, fluorouracil and gemcitabine in advanced pancreatic cancer: a randomized controlled multicentre phase III trial. Lancet Oncol 6:369–376CrossRefPubMedGoogle Scholar
  53. 53.
    Cunningham D, Chau I, Stocken D et al (2005) Phase III randomized comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer 3:4 (PS11)Google Scholar
  54. 54.
    Milella M, Bria E, Carlini P et al (2006) Does a second drug added to gemcitabine (G) improve outcome over G in advanced pancreatic cancer APC? A pooled analysis of 5561 patients enrolled in 16 phase II trials. Ann Oncol 17(Suppl 9): abstract 10740, ESMO 2006Google Scholar
  55. 55.
    Heinemann V, Hinke A, Bock S et al (2006) Meta-analysis of randomized trials. Evaluation of benefit of chemotherapy from combination chemotherapy applied in advanced pancreatic cancer. Ann Oncol 17(Suppl 9): abstract 10730Google Scholar
  56. 56.
    Reni M, Manbrini A, Pasetto L (2006) Salvage therapy in advanced pancreatic adenocarcinoma. Ann Oncol 17(Suppl 9) Abs P1132Google Scholar
  57. 57.
    Herrmann T, Jaeger D, Stremmel SW et al (2007) Second-line chemotherapy in advanced pancreatic cancer: A retrospective, single center analysis. ASCO 2007, abstract 15187. Available at, accessed 28 June 2008Google Scholar
  58. 58.
    Mancuso A, Sacchetta S, Saletti P et al (2007) Clinical and molecular determinants of survival in pancreatic cancer patients treated with second line chemotherapy: results of an Italian/Swiss multicenter survey. J Clin Oncol 25: abstract 4622Google Scholar
  59. 59.
    Gebbia V, Maiello E, Giuliano F et al (2007) Second line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice. Ann Oncol 18:124–127Google Scholar
  60. 60.
    Tsavaris N, Kosas C, Sopelitis H et al (2005) Second line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine pre-treated advanced pancreatic cancer: A phase II study. Invest New Drugs 23:369–375CrossRefPubMedGoogle Scholar
  61. 61.
    Xiong HQ, Wolff RA, Hess KR et al (2006) A phase II trial of oxaliplatin plus capecitabine (xelox) as second line therapy for patients with advanced pancreatic cancer. J Clin Oncol 24(20): abstract 4119Google Scholar
  62. 62.
    Boeck SH, Wilkowski R, Bruns CJ et al (2007) Oral capecitabine in pre-treated gemcitabine patients with advanced pancreatic cancer: a single center study. J Clin Oncol 24(18): abstract 15085Google Scholar
  63. 63.
    Demols A, Peeters M, Polus M et al (2006). Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 94:481–485CrossRefPubMedGoogle Scholar
  64. 64.
    Riess H, Pelzer U, Stieler J et al (2007) A randomized second line trial in patients with gemcitabine refractory advanced pancreatic cancer-CONKO 003. J Clin Oncol 24(18) abstr. 4119Google Scholar
  65. 65.
    Bramhall SR, Rosemurgy A, Brown PD et al (2001) Marimastat as first line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 19:3447–3455PubMedGoogle Scholar
  66. 66.
    Bramhall SR, Schulz J, Nemunaitis J et al (2002) A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161–167CrossRefPubMedGoogle Scholar
  67. 67.
    Van Cutsem E, Van de Velt H, Karasek P et al (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430–1438CrossRefPubMedGoogle Scholar
  68. 68.
    Kindler HL, Niedzwiecki D, Hollis D et al (2007) A double blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB)80303. Gastrointestinal Cancers Symposium abstract 108. Available at, accessed 28 June 2008Google Scholar
  69. 69.
    Wallace JA, Locker G, Nattam S et al (2007) Sorafenib (S) plus gemcitabine (G) for advanced pancreatic cancer (PC): a phase II trial of the University of Chicago Phase II Consortium. Gastrointestinal Cancers Symposium abstact 137. Available at, accessed 28 June 2008Google Scholar
  70. 70.
    Moore MJ, Goldestein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966CrossRefPubMedGoogle Scholar
  71. 71.
    Fountzilas G, Murray S, Xiros N et al (2007) Hellenic Cooperative Oncology Group (HeCOG). Gemcitabine (G) combined with gefitinib in patients with inoperable or metastatic pancreatic cancer. A phase II trial. ASCO abstract 15016. Available at, accessed 28 June 2008Google Scholar
  72. 72.
    Philip PA, Benedetti J, Fenoglio-Preiser C et al (2007) Phase III study of gemcitabine (G) plus cetuximab versus gemcitabine alone in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (P): SWOGs0205 study. ASCO abstr. LBA4509. Available at, accessed 28 June 2008Google Scholar
  73. 73.
    Cascinu S, Berardi R, Siena S et al (2007) The impact of cetuximab on the gemcitabine/cisplatin combination in first line treatment of EGFR-positive advanced pancreatic cancer (APC): a randomized phase II of GISCAD. ASCO abstract 4544. Available at, accessed 28 June 2008Google Scholar
  74. 74.
    Kullmann F, Hollerbach S, Dollinger M et al (2007) etuximab plus gemcitabine/oxaliplatin (GEMOXCET) in 1st line metastatic pancreatic cancer. First results from a multicenter phase II study. Gastrointestinal Cancers Symposium abstract 137Google Scholar
  75. 75.
    Louvet C, Andrè T, Liedo G et al (2002) Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 20:1512–1518CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2009

Authors and Affiliations

  • Mario Scartozzi
    • 1
  • Chiara Pierantoni
    • 1
  • Alessandra Pagliacci
    • 1
  • Stefano Cascinu
    • 1
  1. 1.Department of Oncology, Ospedali Riuniti University HospitalPolytechnic University of MarcheAnconaItaly

Personalised recommendations